During the 1990's, despite scientific advances in the understanding of the mechanisms and pathophysiology of acute central nervous system injury, clinical trials of novel neuroprotective drugs yielded disappointing results. This book seeks to explore the issues surrounding this area of research and therapeutic development, by applying more than 20 years of clinical trial experience in the area of acute neurology and neurosurgery. The book applies lessons learned from the clinical setting from neuroemergencies such as acute stroke and traumatic brain injury, to the improvement of research methodologies and strategies used in developing novel therapies. From the knowledge of clinical assessment using standardized tools, to the intricate design of difficult hyper-acute neuroemergencies trials, the reader will benefit from the perspectives provided.
- No. of pages:
- © Academic Press 2006
- 15th December 2005
- Academic Press
- eBook ISBN:
- Hardcover ISBN:
Dr. Alves is Vice President of Clinical Operations at Evoke Pharmaceuticals, Inc. in Solana, California. He has held academic positions conducting basic clinical research in neuroemergency populations, and has served as consultant to numerous companies seeking to develop novel drugs.
Valeant Pharmaceuticals Inc., Costa Mesa, CA, USA
Dr. Skolnick is a Clinical Associate Professor of Neurosurgery at North Shore-LIJ School of Medicine in Manhasset, New York. He has a broad based experience with development responsibilities in neurology that includes Intracerebral hemorrhage, traumatic brain injury and stroke as well as more recently in the area of inflammation having worked on the development of multiple monoclonal antibodies in Psoriasis, Rheumatoid Arthritis, Crohn’s disease and Ulcerative Colitis. Dr. Skolnick has previously worked as a clinical development consultant to pharmaceutical companies with a focus on early novel drug development.
Novo Nordisk Pharmaceuticals, Inc., Princeton, NJ, USA